Top Stories Wednesday, November 16, 2016 China has beaten out U.S. academics and biotechs to become the first in testing new gene editing tech known as CRISPR-Cas9 in humans. Wednesday, November 16, 2016 Bristol-Myers Squibb has teamed with Enterome to discover microbiome-derived biomarkers, drug targets and bioactive molecules relevant to its immuno-oncology operation. The alliance positions Bristol-Myers to try to harness the potentially modulating effect of the gut microbiome on cancer immunotherapies. Wednesday, November 16, 2016 A Phase IIb trial of CSL Behring’s post-heart attack protection candidate met its co-primary safety endpoints. The result, when paired to data supporting the mechanism of action, prompted CSL to start looking toward a Phase III trial, despite the drug failing to best placebo in a secondary efficacy endpoint. Wednesday, November 16, 2016 In its Series A announced today Glycomine, an early-stage biotech working on replacement therapies for rare diseases, raised $12 million with help from Sanderling Ventures and Chiesi Ventures. Wednesday, November 16, 2016 Positive mid-stage data has put The Medicines Company and partner Alnylam on course to start Phase III trials of a PCSK9-targeting drug that could be dosed just two or three times a year. Wednesday, November 16, 2016 Another day, another advancement for Roche’s biosimilar challengers—and this time, they’re coming after Avastin. Wednesday, November 16, 2016 Novartis’ Cosentyx and Celgene’s Otezla aren’t just battling it out in the psoriasis arena. As of early this year, they’re competing in psoriatic arthritis, too—and each drugmaker made its case this week with new data in that disease. Wednesday, November 16, 2016 While we’re used to getting smartphone software updates wirelessly, the same couldn’t be said for blood glucose meters—until now. Livongo is rolling out its second-gen glucose meter with “over-the-air” capabilities, enabling users to receive updates on the go and manage their diabetes even better. | | | New York-based oncology biotech BeyondSpring has filed with the SEC for a $100 million IPO. Story Marina Biotech has closed a merger deal with IthenaPharma as the pair eye 2019 as the year for their first two launches. Release Agilis Biotherapeutics says it has treated its first patient in a midstage test of its gene therapy for AADC deficiency, AGIL-AADC. Statement | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Presented by: Biotech Primer This 3-part webinar series is specifically geared toward the non-science professional who needs to better understand industry terminology, science, techniques and issues. Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. 24th International Molecular Medicine Tri-Conference February 19-24, 2017 | Moscone North Convention Center | San Francisco, CA FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Drug Development Boot CampTM 2016 November 16-17, 2016 | Boston, MA Fierce Innovation Awards: Life Sciences Edition 2016 Application Deadline: Friday, December 2nd Discover the Richness of Latin America November 29–30, 2016 | San Juan, Puerto Rico Immunotherapy: Mapping the Future of Cancer Drug Discovery November 28, 2016 | Munich, Germany | 